Brainsway Stock Current Asset
| BRSYF Stock | USD 8.53 0.00 0.00% |
BrainsWay fundamentals help investors to digest information that contributes to BrainsWay's financial success or failures. It also enables traders to predict the movement of BrainsWay Pink Sheet. The fundamental analysis module provides a way to measure BrainsWay's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BrainsWay pink sheet.
BrainsWay |
BrainsWay Company Current Asset Analysis
BrainsWay's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current BrainsWay Current Asset | 14 M |
Most of BrainsWay's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BrainsWay is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, BrainsWay has a Current Asset of 14 M. This is 99.35% lower than that of the Healthcare sector and 99.3% lower than that of the Medical Devices industry. The current asset for all United States stocks is 99.85% higher than that of the company.
Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
BrainsWay Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 | |||
| Profit Margin | (0.37) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | (24.98 M) | |||
| Shares Outstanding | 33.08 M | |||
| Shares Owned By Insiders | 19.83 % | |||
| Shares Owned By Institutions | 1.11 % | |||
| Price To Earning | (23.91) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 1.11 X | |||
| Revenue | 29.66 M | |||
| Gross Profit | 24.35 M | |||
| EBITDA | (3.31 M) | |||
| Net Income | (6.46 M) | |||
| Cash And Equivalents | 52.45 M | |||
| Cash Per Share | 1.50 X | |||
| Total Debt | 754 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 7.71 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | 884 K | |||
| Earnings Per Share | (0.22) X | |||
| Target Price | 10.75 | |||
| Number Of Employees | 118 | |||
| Beta | 0.2 | |||
| Market Capitalization | 35.72 M | |||
| Total Asset | 75.73 M | |||
| Retained Earnings | (47 M) | |||
| Working Capital | 10 M | |||
| Current Asset | 14 M | |||
| Current Liabilities | 4 M | |||
| Z Score | 28.2 | |||
| Net Asset | 75.73 M |
About BrainsWay Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BrainsWay's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BrainsWay using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BrainsWay based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BrainsWay Pink Sheet
When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.